Project Grant R01CA304154
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $638,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award supports fundamental research investigating the mechanisms of ovarian cancer metastasis, specifically examining how detachment-sensing proteins, particularly the atypical GTPase RhoV, facilitate peritoneal metastasis in high-grade serous...
- Federal Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award funds an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific genetic dependencies in hepatocellular carcinoma (HCC). The research employs a hybrid computational and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh $109,076 under the Cancer Research Manpower program (CFDA 93.398) on January 21, 2026, with a completion date of July 31, 2029. This project grant funds research to develop innovative computational and analytical tools for tracking metastatic breast cancer subclones and predicting therapeutic vulnerabilities. The research integrates machine learning techniques, including transformer...
- Federal Grant Award Summary The University of Pittsburgh received a $435,788 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop novel therapeutic approaches targeting mutant isocitrate dehydrogenase (IDH) enzymes in cancer patients. The grant, awarded April 1, 2026, with a completion date of March 31, 2031, supports the discovery and development of active site-directed inhibitors and proteolysis targeting chimeras (PROTACs)...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2027. The award supports development of an integrative framework for surface protein imputation in spatial biology applications. The project will advance understanding of tumor microenvironments by creating machine learning approaches to predict surface protein...
- Federal Grant Award Summary The University of Pittsburgh received a $151,920 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on HCK (a Src-family kinase implicated in acute myeloid leukemia). The research addresses a significant clinical...
- Summary of Federal Project Grant Award The University of Pittsburgh received a $141,566 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on March 24, 2026, with completion targeted for February 28, 2028. This K99/R00 Pathway to Independence Award supports biomedical research training and career development in cancer research, specifically focusing on investigating the conformational landscape and regulation of small GTPases...
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $412,856 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, for a 24-month performance period concluding April 30, 2028. This award funds research investigating the role of cell cycle plasticity in bladder cancer growth and progression through advanced single-cell spatial proteomics and machine learning methodologies. The project will generate a systematic...
- Federal Grant Award Summary The University of Pittsburgh received a $658,492 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion targeted for February 28, 2031. This award supports research and development of a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC), including castration-resistant prostate cancer-adenocarcinoma (CRPC-ADENO) and neuroendocrine...